TABLE 2.
Baseline participant characteristics
| Intervention | OF (n = 23) | Maltodextrin (n = 23) | OF/2’FL (n = 23) | 2’FL (n = 23) | Cohort (overall) (n = 92) |
|---|---|---|---|---|---|
| Age (y) | 29.17 (19–50) | 29.04 (20–47) | 25.39 (19–47) | 28.91 (19–46) | 28.13 (19–50) |
| Weight (kg) | 65.98 (53.34–105.00) | 69.23 (50.00–94.00) | 67.95 (48.20–100.00) | 64.53 (46.00–93.50) | 66.92 (46.00–105.00) |
| Height (cm) | 169.80 (157.00–196.00) | 167.70 (145.00–193.00) | 168.50 (154.00–187.00) | 166.30 (155.00–181.00) | 168.08 (145.00–196.00) |
| BMI (kg/m2) | 22.79 (18.72–29.07) | 24.41 (19.02–28.73) | 23.74 (19.84–29.96) | 23.17 (18.59–29.73) | 23.53 (18.59–29.96) |
Mean and range segregated by intervention (n = 23 per group) and total cohort (n = 92). Abbreviations: 2’FL, 2’fucosyllactose; OF, oligofructose; OF/2’FL, oligofructose/2’fucosyllactose.